Background. The assessment of antibody responses after immunization with radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (Sanaria PfSPZ Vaccine) has focused on IgG isotype antibodies. Here, we aimed to investigate if P. falciparum sporozoite binding and invasion-inhibitory IgM antibodies are induced following immunization of malaria-preexposed volunteers with PfSPZ Vaccine.
with no CHMI protection data yet reported [16] . However, most of these live-attenuated malaria vaccinations followed by CHMI have been performed in malaria-naive volunteers living in malaria-free countries [5] [6] [7] [8] [9] [10] [11] [13] [14] [15] . In the first report of immunization of Africans (Malians) with life-long previous exposure to P. falciparum malaria, protection against P. falciparum infection was significant [12] . However, antibody responses to PfCSP by enzyme-linked immunosorbent assay (ELISA), PfSPZ by immunofluorescence assay (IFA), and to PfSPZ by inhibition of sporozoite invasion (ISI) assay were much lower in Malians than in nonimmune American adults who received the exact same PfSPZ Vaccine immunization regimen. This was hypothesized to be a result of immune dysregulation due to lifelong exposure to P. falciparum [12] . It could also be due to anti-P. falciparum sporozoite antibody and anti-liver stage T-cell responses that develop during natural infection [17] [18] [19] [20] and/or the fact that prior exposure to blood stage infection might hamper malaria vaccine-induced protection [21] . We propose that better understanding of the type, kinetics, and maintenance of malaria-specific immune responses in malaria-preexposed populations after immunization could improve the development and successful deployment of malaria vaccines [22] . It is thought that the major driver of the powerful protection seen after immunization with PfSPZ-based vaccines is cellular immunity [13] . However, both anti-CSP monoclonal antibodies and IgG from PfSPZ-immunized volunteers can strongly inhibit P. falciparum sporozoite infection of hepatocytes after passive transfer into humanized liver mice, arguing for a role for antibodies in protection [9, 23, 24] . As mentioned above, immunization of previously malaria-exposed volunteers resulted in weaker antisporozoite antibody responses. These studies, however, only focused on IgG responses and recent reports suggest that exposure to blood stage infection results in a significant antiparasite IgM response [21, 25] .
Here, we aimed to determine (i) if PfSPZ-specific IgM antibodies were induced by immunization with PfSPZ Vaccine and (ii) if these IgM antibodies had functional activity in inhibiting P. falciparum sporozoite invasion of hepatocytes. To do so, we used sera collected during a clinical trial investigating the safety, immunogenicity, and protective efficacy of DVI-administered PfSPZ Vaccine in Tanzanian adults in Bagamoyo, Tanzania (NCT02132299) (Jongo et al, manuscript submitted).
METHODS
Detailed experimental methods can be found in the Supplementary Methods.
Ethics Statement
All volunteers gave written informed consent before screening. 
Clinical Trial Design and Study Population
Details of the trial procedure and volunteers enrolled are given elsewhere (Jongo et al, manuscript submitted). In summary, healthy male volunteers aged 20 to 30 years were randomized to DVI of 5 doses of normal saline, or 1.35 × 10 5 or 2.7 × 10 5 of PfSPZ Vaccine in a double-blind clinical trial at the Bagamoyo Clinical Trial Unit of the Ifakara Health Institute in Bagamoyo, Tanzania between 2014 and 2015. Vaccine efficacy was assessed by CHMI by DVI of 3200 PfSPZ of PfSPZ Challenge at 3 weeks after the last PfSPZ immunization, with protected volunteers receiving a second CHMI 24 weeks after the last PfSPZ immunization. The PfSPZ Vaccine proved to be safe and well tolerated in all Tanzanian volunteers. In the low-dose group, 1 volunteer of 18 (6%) was protected against CHMI at 3 weeks and 4 of 20 (20%) volunteers were protected at 3 and 24 weeks in the high-dose group.
Inhibition of Sporozoite Invasion Assay
To determine the capacity of serum antibodies to inhibit sporozoite invasion in vitro, a previously described flow cytometry-based assay was performed [16, 26] . Percent of inhibition of invasion for each volunteer was determined by normalizing to wells containing volunteer-matched preimmune serum or a pooled serum sample from malaria-naive individuals. Normalization of all postimmune ISI values was done as follows: [(%ISI)/(%ISI baseline)] × 100.
CSP Enzyme-Linked Immunosorbent Assay
IgG and IgM antibodies were measured against full-length PfCSP protein, as previously described with minor modifications [16] . All ELISA values were repeated and are referred to as the mean of 2 independent runs. Not all volunteers were tested at all the time points due to sample availability.
Generation of IgM Antibody Fractions
IgM antibody fractions were generated by depletion of IgG and IgA using protein G and Jacalin-sepharose, respectively. Purity of fractions was assessed using total human IgM and IgA ELISAs (Bethyl Laboratories) according to the manufacturer's protocol.
Sporozoite Immunofluorescence Assays
Sporozoite IFAs were performed as previously described using freshly dissected P. falciparum sporozoites [16] . Sporozoites were visualized using Deltavision microscopy. Images were captured using the same exact exposure conditions in the hIgM/ Alexafluor-594 channel to allow comparisons of intensity across samples. Images were modified for clarity with the same exact parameters applied to each sample.
Complement Fixation Assay
The ability of IgM antibody fractions to fix complement was assessed using plate-bound whole P. falciparum sporozoites. C5a was detected in the supernatant following incubation of IgM fractions with human serum complement (Quidel Corp.) by ELISA.
Statistical Analysis
Statistical analyses were carried out using R [27] . The R package ggplot2 was used for data visualization [28] as well as GraphPad Prism 6.
RESULTS

Immunization With PfSPZ Vaccine Induces Sporozoite Inhibitory
Antibodies
An overview of the vaccination schedule followed by 2 consecutive homologous CHMIs is given in Supplementary Figure 1 as well as in the publication detailing the clinical trial and protection results (Jongo et al, submitted). Briefly, 2 groups of volunteers (n = 20) were vaccinated 5 times each with a dosage of 1.35 × 10 5 (low dose) or 2.7 × 10 5 (high dose) PfSPZ Vaccine and given controlled human malaria infection (CHMI) by direct venous injection of aseptic, purified, cryopreserved wild type sporozoites (PfSPZ challenge) [22] . Volunteers protected from this first CHMI (CHMI1) were then rechallenged 140 days later in a second CHMI (CHMI2), again by PfSPZ challenge.
To verify the inhibitory capacity of serum from PfSPZ vaccinated volunteers reported in Jongo et al (manuscript submitted) in our hands, we used a previously described flow cytometry-based inhibition assay of P. falciparum sporozoite invasion of HC04 cells (ISI assay) [16, 26] . There was variable preexisiting ISI activity in a subset of volunteers as measured using serum from baseline (Supplementary Figure 2) . Thus, in order to measure vaccine-induced changes in serum reactivity we normalized each time point to the inhibitory activity of serum taken at baseline.
After the third immunization, immunized volunteers in the low-dose group showed an average inhibition of 53.75% ± 10.81% ( Figure 1A ) while immunized volunteers from the high-dose group showed inhibition by an average of 52.73% ± 5.14% ( Figure 1B ). Two volunteers from the low-dose group and 1 from the high-dose group showed no ISI activity at this time point. After the fifth immunization, all volunteers in both groups developed functional antibodies with an average inhibition of 62.93% ± 6.36% for the low-dose group and 61.47% ± 3.55% for the high-dose group. ISI activity was unchanged after CHMI1 and was sustained until day 140 after CHMI1 in protected volunteers with an average inhibition of 75.60% ± 7.89%. ISI results of serum samples collected from placebo controls remained undetectable during PfSPZ vaccinations but did increase significantly after CHMI1 ( Figure 1C) .
Collectively, these results demonstrate that PfSPZ vaccination of malaria-preexposed Tanzanian volunteers induced antibodies that inhibit P. falciparum sporozoite invasion in vitro, in agreement with results of Jongo et al (submitted) using the same samples with an ISI method used across other PfSPZ clinical trials.
PfSPZ Vaccination Induces Anti-PfCSP IgM Antibodies
PfCSP is the major, immunodominant protein on the surface of P. falciparum sporozoites [29] . Thus, we assessed the IgG and IgM antibody titers specific for full-length recombinant PfCSP (amino acids 21-289) [16] using ELISA.
We first verified the presence of anti-PfCSP IgG, as reported in Jongo et al (submitted). We set the positivity cutoff for anti-PfCSP IgG antibody titers at 10.12 arbitrary units (AU) (Figure 2A ) based on optimization with malaria-naive volunteers [16] . At baseline, 4 of 23 volunteers showed positive IgG titers (average of 18.89 ± 1.84 AU) with a total group average of 7.94 ± 1.15 AU ( Next, we wanted to determine if anti-PfCSP IgM responses were also generated after PfSPZ vaccination. The positivity cutoff for anti-PfCSP IgM antibody titers was set at 9.21 AU based on optimization with malaria-naive serum. At baseline, CSP-binding IgM antibodies ( Figure 2B ) were detected in 4 of 23 volunteers with an average of 12.78 ± 1.83 AU while the total group average was 7.39 ± 0.71 AU. Fourteen days after the fifth immunization, 18 of 23 volunteers were positive for antiPfCSP IgM titers with an average of 89.61 ± 27.30 AU. Three of 4 placebo controls remained negative at this time point, as well as 1 vaccinee. Twenty-eight days post CHMI1, a significant increase in anti-PfCSP IgM titers was seen in all volunteers that experienced asexual blood stage infections, including nonprotected vacinees (average: 157.88 ± 34.71 AU) and placebo controls (average: 152.71 ± 54.50 AU) but no increase in anti-CSP IgM was seen in protected volunteers who remained free of parasitemia. In serum samples collected 140 days after CHMI1 and 28 days after CHMI2, these anti-PfCSP IgM responses persisted in 3 of the 4 volunteers sampled at this time point, which was 189 days after the final immunization (Supplementary Figure 1) .
Overall, these results revealed that in addition to IgG, malaria pre-exposed Tanzanian adults developed anti-PfCSP IgM antibody titers that persisted for more than 6 months after PfSPZ immunization and were boosted following exposure to blood stage parasites. No significant correlation became apparent between invasion inhibition and either anti-PfCSP IgG ( Figure 3A) or IgM titers ( Figure 3B ).
Antisporozoite IgM Antibodies Contribute to Inhibition of Sporozoite
Invasion and Fix Complement
Next, we wanted to understand better the potential contribution of vaccine-induced anti-PfCSP IgM antibodies to in vitro sporozoite invasion inhibition. Here, we selected plasma samples collected from 5 volunteers in the high-dose group whose serum was inhibitory in vitro and had positive anti-PfCSP IgM titers and low antiPfCSP IgG 14 days after the fifth immunization. Plasma samples were depleted of IgG and IgA antibodies and the IgM-enriched fractions were used to test for function in ISI assay, whole P. falciparum sporozoites in IFA, and binding against full-length PfCSP in ELISA (Figure 4A-C) . The resulting fractions after IgG and IgA depletion contained IgM antibodies with a median of 96.6 ± 7.7% pure IgM as measured by total IgM and IgA ELISA (Supplementary Table 1 ). Given the wide variation in total IgM concentrations found in human serum [30] , we chose to test the IgM fractions at a volume-based dilution of 1:20 calculated using the original starting , and day 28 post-CHMI2. Antibody titers are specified as arbitrary units (AU) with a positivity cutoff shown by a dashed line. Each data point represents the mean of the duplicate ELISA titers for 1 volunteer. Asterisks indicate statistically significant difference of the mean antibody titer compared to the mean titer measured at the pre-immunization time point as determined by paired t test. Bars with asterisks indicate statistically significant difference of the mean antibody titer between visits determined by paired t test. *P ≤ .05, **P ≤ .01, ***P ≤ .001. The small sample size of control and protected subjects did not allow for statistical testing when grouped by protection status. For whole-group analyses, see Supplementary Figure 3 . Control volunteers are shown as crossed circles (n = 4) in the left panel, immunized nonprotected volunteers as solid circles (n = 16) in the middle panel, and immunized protected (n = 4) as empty triangles in the right panel. Serum samples of 2 volunteers were not available, one at baseline (protected subject) and one at visit of day 14 post-fifth (nonprotected subject). The 2 volunteers were not considered for statistical analysis.
volume of plasma, which was the same dilution used for serum in Figure 1 . At a 1:20 dilution the IgM-enriched preparation inhibited P. falciparum sporozoite invasion in 3 out of 5 volunteers, ranging between 28% and 43% ( Figure 4A ). The 3 ISI-positive volunteers had the highest pre-enrichment serum anti-PfCSP IgM titers (average of 304 AU) while the 2 ISI-negative volunteers had an average of 104 AU. IgM-enriched preparations of these 3 positive volunteers also were positive in sporozoite IFA and had the strongest binding to PfCSP by ELISA ( Figure 4B and C). IgM fractions from plasma samples of the 4 high-dose protected volunteers collected 140 days after the first CHMI were tested as well. One volunteer with high anti-PfCSP IgM titers at this time point showed strong binding to purified sporozoites by IFA and showed invasion inhibition at 31% (data not shown).
As IgM antibodies are extremely efficient at fixing complement [31] , we also wanted to determine if IgM induced after vaccination could fix complement after binding to P. falciparum sporozoites. Indeed, following binding to plate-bound whole P. falciparum sporozoites, we were able to detect complement fixation by C5a release in supernatants in a manner that correlated with both anti-PfCSP IgM titer and IFA/ISI positivity ( Figure 4D ).
In summary, PfSPZ Vaccine-induced anti-PfCSP IgM antibodies in malaria-preexposed volunteers, which persist up to 140 days after CHMI, are capable of binding P. falciparum sporozoites, inhibiting in vitro P. falciparum sporozoite invasion, and fixing complement after P. falciparum sporozoite binding.
DISCUSSION
PfCSP is the most immunodominant antigen expressed on the P. falciparum sporozoite surface [29] and previous studies of PfSPZ Vaccine, including those in Africa, have focused on IgG antibodies to PfCSP [8] [9] [10] [11] [12] . In addition to anti-PfCSP IgG responses, we assessed IgM antibodies following PfSPZ vaccination. All immunized volunteers mounted anti-PfCSP IgG antibodies, consistent with previous reports (Jongo et al, manuscript submitted), while 17 of 19 immunized volunteers made anti-PfCSP IgM antibodies (Figure 2A, B) . As we saw ISI activity in serum samples from volunteers with high IgM and low IgG titers against PfCSP, we hypothesized that the IgM fraction could be contributing to antibody function in vitro. Indeed, we demonstrated that in 3 volunteers, these anti-PfCSP IgM antibodies mediated ISI activity in plasma fractions after depletion of IgG and IgA. To our knowledge, this is the first demonstration of P. falciparum sporozoite inhibition mediated by enriched IgM preparations. We did not find correlations between anti-PfCSP IgG or IgM titers and ISI activity of whole serum ( Figure 3A, B) . This is not surprising given that we show that PfSPZ vaccination elicits a complex antibody response composed of both IgG and IgM, and that immunization with irradiated sporozoites elicits responses to a number of antigens [32] . Thus, it is unlikely that a single component will correlate with antibody function in a cohort of vaccinees.
Vaccine-induced IgM antibodies have been regarded in the past as short-lived and less affinity-matured compared to IgG antibodies [33] , and early studies of naturally acquired antibodies to PfCSP in Indonesia [34] and Kenya [35] showed that IgM responses were of lower prevalence and magnitude than IgG responses. Therefore, investigation of vaccine-induced humoral immunity has focused on IgG isotypes in malaria-exposed and malaria-naive populations [2, 8-12, 24, 36-38] . Indeed, PfCSP or P. falciparum sporozoite-binding IgG antibodies have correlated with protection in some studies of PfSPZ Vaccine [8, 9, 12] and to some extent in the PfCSP subunit vaccine RTS,S [38] . However, in one study using radiation attenuation sporozoites (RAS)-immunized mice, IgM-dominated antibodies were described as binding to live P. yoelii sporozoites and limiting parasite liver infection by 74% in passive transfer experiments [39] . IgM antibodies cross-reacting with glycoproteins on the P. yoelii sporozoite surface have also been shown to inhibit parasite infection of hepatocytes in vivo and in vitro [40] . In the latter example, these antibodies appeared to function largely through FC-dependent effectors and complement fixation with recruitment of polymorphonuclear cells [40] . Outside of malaria, plasma cells secreting IgM antibodies that are somatically hypermutated and that reside in the spleen have been detected during vaccination and in influenza virus and lymphocytic choriomeningitis virus infections [41] .
Blood stage infection can result in IgM memory B cells that are long-lived and somatically hypermutated in humans, and the resulting IgM antibodies can contribute to protection from asexual blood stage infection in mice [25] . Additionally, blood stage infection can also alter germinal center formation and acquisition of antibodies to the pre-erythrocytic stages [21] . However, the development of functional anti-sporozoite IgM responses as a result of blood stage infection has not been investigated. Interestingly, in our study we observed a boost in anti-PfCSP IgM and not IgG after CHMI only in those volunteers that experienced blood stage infection (Figure 2 ). Thus, it is possible that in our study, prior exposure to blood stage malaria could explain the predisposition of these volunteers to developing anti-CSP IgM in this population as blood stage infection appears to skew the immune response to IgM antibodies. However, this will require similar studies in malaria-naive populations. Importantly, our data suggest that P. falciparum sporozoite-binding and invasion-inhibitory IgM could contribute to protection against malaria infection. IgM antibodies are excellent in fixing complement, which could either eliminate circulating P. falciparum sporozoites by formation of the membrane attack complex leading to parasite lysis, or by formation of C5a, C3a, and other byproducts, which can subsequently recruit mononuclear cells and stimulate phagocytosis. While complement-mediated lysis has been demonstrated for asexual blood stage merozoites in rodents and using human serum [42, 43] , definitive evidence of complement fixation at the sporozoite stage is sparse. Interestingly, we demonstrate here that vaccine-induced IgM antibodies were able to fix complement following binding to whole P. falciparum sporozoites ( Figure 4D ). To our knowledge, this is the first demonstration of complement fixation with P. falciparum sporozoites and the first to show this using antibodies from humans. Two reports have demonstrated apparent complement-dependent disruption of avian and rodent sporozoite morphology [44, 45] , but this was not directly assessed for complement fixation by observing complement byproducts. However, one study in rodents did demonstrate complement C3b deposition on sporozoites after passive transfer of anti-alpha-gal antibodies and a dependence on complement for the protective efficacy of these antibodies [40] . Thus, it is possible that these IgM antibodies could be functioning in prevention of infection in humans as it is conceivable that sporozoites could encounter IgM and complement during their journey from the skin to the liver parenchyma. Directly assessing the role of IgM binding and complement fixation in the prevention of P. falciparum sporozoite infection in vivo will be challenging as laboratory mice have relatively low levels of complement activity [46] , particularly in the classical pathway with human antibodies [47] . Nevertheless, determining whether this can be a relevant effector mechanism in protection against P. falciparum sporozoite infection will be critical for better understanding antibody-mediated protection after whole sporozoite immunization, especially in previously malaria-infected individuals. This can be accomplished by carefully designed murine in vivo studies as well as future in vitro studies to determine if the inclusion of complement reveals previously unobserved antisporozoite antibody activity such as has been demonstrated for blood stages [43] .
CONCLUSIONS
Immunization of malaria-preexposed volunteers with PfSPZ Vaccine elicits functional, sporozoite invasion-inhibitory antibodies, including anti-PfCSP IgM antibodies capable of fixing complement in vitro. Immunological assessment of the mode of action of PfSPZ vaccine-induced humoral effector mechanisms should therefore include monitoring of parasite-specific IgG as well as IgM antibodies. Future studies need to expand on our findings and address if (1) parasite-inhibitory IgM production is related to PfSPZ vaccine administration route and dosing; (2) PfSPZ vaccine-induced IgM responses are unique to malaria-preexposed individuals; and (3) the sporozoite-binding IgM antibody repertoire undergoes affinity maturation resulting in improved effector function over repeated vaccinations.
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